CFTR corrector

May 29, 2019May 29, 2019

ABBV-2222 Partially Corrects CFTR Function in CF Patients, Phase 2 Trials Show

cystic fibrosis, News

Treatment with ABBV-2222, an investigational CFTR corrector formerly known as GLPG2222, was well-tolerated and partially corrected the function of the CFTR protein, both alone and in combination with Kalydeco ... Read more

July 6, 2018November 5, 2018

GLPG2737 Add-on Increases Effectiveness of Orkambi for Cystic Fibrosis, Phase 2 Results Show

News

Adding GLPG2737, Galapagos’ investigational CFTR corrector, to Vertex’s Orkambi (lumacaftor/ivacaftor) enhances the effectiveness of the treatment in cystic fibrosis patients with two copies of the F508del mutation, topline results from ... Read more

November 22, 2017November 22, 2017

GLPG2222 Plus Kalydeco Shows Positive Clinical Results in Phase 2 Trial, Galapagos Reports

cystic fibrosis, News

Adding investigational CFTR corrector GLPG2222 safely improved disease parameters in cystic fibrosis (CF) patients treated with Kalydeco (ivacaftor), reported the therapy’s Belgian developer, Galapagos, citing Phase 2 clinical trial data. The ... Read more

October 28, 2016October 28, 2016

#NACFC2016 – CFTR Potentiators, Correctors Explored for Rare Mutations in CF

News

Among people with rare mutations in the CFTR gene, the gene defective in cystic fibrosis (CF), studies are needed to map down which patients may benefit from CFTR potentiators, ... Read more

April 4, 2016April 4, 2016

Proteostasis Therapeutics Releases Early Data Showing Its CFTR Protein Amplifier and Corrector May Effectively Treat CF

News

Proteostasis Therapeutics, Inc., recently presented new and promising early data on its genotype-agnostic amplifier and novel corrector of the cystic fibrosis transmembrane conductance regulator (CFTR), the protein defective in ... Read more

February 15, 2016February 15, 2016

Mild Cystic Fibrosis in Pediatric Patient Found to Be Caused by Rare Gene Mutation

cystic fibrosis, News

Researchers identified a novel, rare mutation causing cystic fibrosis (CF) in a pediatric African-American patient. The mutation, however, was found to be responsive to the CFTR corrector VX-809, therefore ... Read more

Pin It on Pinterest